申请人:QILU REGOR THERAPEUTICS INC.
公开号:US20220389037A1
公开(公告)日:2022-12-08
Provided herein is a compound represented by structural formula (I-0) or formula (II): or a pharmaceutically acceptable salt or a stereoisomer thereof useful for treating diseases (such as cancer) that are treatable by inhibiting HPK1 activity.